1DepaUniver

Introdpatientclinicadoses oMethomicro-0.156xDTPA weightnormalResulton T2- summaBoth Hregion While compa(p< 0.01 and cfrom hWherelow dotreatmeDiscusperfusiconvenradiatio

RefereMontreAckno

Fig. (D) thera

Detecting E

Vickie Zhangrtment of Radiologrsity of California,

duction: Radiationts suffer post-treatmal disease-free survof radiation therapods: A TRAMP moimaging spectrom

x0.312x1mm). [1-1

(Magnevist, Bayeted gradient echo slized to maximumt: Fig. 2 shows lacweighted images

ary from high (14-HP markers showe

decreased by day lac/pyr ratio from

are to day 0 (p< 0.001), and subsequencontinued to increa

high dose region sias DCE AUC from

ose regions initiallyent. ssion: These resultion in tumor exposntional 1H MR maron therapy.

ence: 1. Martinez Aeal, 2011, p3161. owledgments: Thi

2: Lac/pyr (A), urimages from day 0apy

Early Tumor R

g1,2, Robert Bok1, gy and Biomedica, San Francisco -

n therapy remains oment cancer recurr

vival for locally adpy in TRAMP tumoouse tumor (size =

meter (Varian Inc.).3C]pyruvate and 1

er HealthCare), dynsequence (TE/TR=

m HP urea in the kid/pyr ratio, urea, arat baseline, 1, 4, a-8Gy) and low dosd significant dose 1 after treatment alow dose region in

01). HP urea from ntly returned to baase (p< 0.01). AUCgnificantly decream low dose region y decreased and re

ts suggest HP biomsed to varying radirkers. Ongoing stu

AA, et. al. Int. J. R 3. Sukumar S et. s project was fund

rea (B), DCE AUC0, 1, 4, and 8 days

Response of P

Subramaniam Sukl Imaging, UniversUniversity of Calif

S

one of the most corence. Clinical dos

dvanced prostate caors using multi-pa

= 3.5cc) was expos Diffusion weight3C Urea were hypenamic contrast enh

=1.11/39ms, 0.312dney. rea under curve (And 8 days after rade (8-4 Gy) regionsdependent change

and continued to dnitially increased bthe high dose regiseline level. HP urC calculated from se on day 1 after trcontinuously incr

eturned to baseline

markers are sensitiiation dose levels. udies are investigat

Radiation Oncologal. Proceedings of

ded by the grant RO

C (C) and ADC after radiation

Prostate CanceHyperpolari

kumar1, Adam Cunsity of California, fornia, Berkeley, BSan Francisco, San

ommon definite trese-escalation trialsancer patients [1]. arametric 14T 1H &sed to varying doseed imaging (DWI)erpolarized and 3Dhancement imaginx0.312x1mm). Th

AUC) calculated frodiation therapy. Fis of tumor at 1 to 8es over time (p< 0.decrease on day 4 &by day 1, and subsion showed signifirea from low dose 1H DCE showed sreatment and retur

reased over time (pe level and higher b

ive to the early chaHP 13C biomarkerting the ability of

gy Biol. 2011;79(2f the 19th Annual MO1EB007588

Fig 3: % chadays after treSignificantlydose regions

er to Radiatioized 13C MR Inha3, I-C. Hsu3, JeaSan Francisco, Sa

Berkeley, CA, Unitn Francisco, CA, U

eatments for prostas reported that highThe purpose of th

& hyperpolarized (es of radiation as s) data were acquireD imaging data weng (DCE) was acquhe signal intensity o

om DCE and ADCg. 3 provides a qu8 days after treatm01). Lac/pyr ratio & 8 (p< 0.01 comsequently decreaseicant decrease 1 dalevel significantly

similar result as Hrned to baseline levp< 0.01), ADC froby day 8 following

anges in metabolisrs correlated with multi-parametric 1

2):363-370 2. ZhanMeeting of ISMRM

ange from baselineeatment in tumor ry different from ba.

on Therapy usImaging an Pouliot2,3, Danian Francisco, CA, ted States, 3DepartUnited States

ate cancer, but desher radiation doses

his study was to inv(HP) 13C MR imagshown in Fig. 1 [2ed using a spin-echere acquired as desuired using a T1-of HP urea was

C images overlaid uantitative ment.

from high dose mpare to day 0). ed by day 4 & 8 ay after therapy y increased on day

HP urea. DCE AUCevel over time. om both high and g

sm and

1H and HP 13C MR

ng VY et. al. ProcM, Montreal, 2011

Figaxi

e of lac/pyr (A), urregions receiving haseline level. +: Sig

ing Multi-Par

iel B. Vigneron1,2, United States, 2Gtment of Radiation

spite excellent succs significantly impvestigate early resging. 2]. Imaging studiesho pulse sequencescribed previously

y C

R in planning and m

ceedings of the 19t

1, p3531

g. 1: Dose distribual image of TRAM

rea (B), ADC (C) &high (red) and lowgnificantly differe

rametric 14T 1

and John KurhaneGraduate Program n Oncology, Unive

cess rates, a signifprove biochemical ponse to the impac

s were performed oe (TE/TR=20ms/1.y [2,3]. Following i

monitoring of pros

th Annual Meeting

ution diagram overMP mouse tumor

& DCE AUC (D) w (blue) dose radiatent between high an

1H and

ewicz1,2 in Bioengineering

ersity of California

ficant number of control and

ct of increasing

on a 14T, 600WB .2s, injection of Gd-

state cancer

of ISMRM,

rlaid on the MR

from 1-8 tion. *: nd lose

g, a,

4319Proc. Intl. Soc. Mag. Reson. Med. 20 (2012)